Astellas pursues legal action over US tacrolimus petition
This article was originally published in Scrip
Executive Summary
Astellas is to take legal action against the US FDA after the agency partly denied the company's 2007 citizen's petition requesting bioequivalence studies in transplant patients for generic versions of its immunosuppressant Prograf (tacrolimus).